FAP targeted nuclear diagnostics and therapy in metastatic ovarian adenocarcinoma

Fibroblast activation protein targeted nuclear theranostics in metastatic ovarian adenocarcinoma: a prospective study. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/113313

Enrollment

Registered

2026-07-03

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C569- Malignant neoplasm of unspecifiedovary

Interventions

Intervention1: FAPi-46/FAP-2286 (68Ga and 177Lu): 68Ga-FAPi and 18F-FDG for imaging 177Lu-FAPi for therapy 68Ga FAPi for imaging - 5mCi- given Intravenously, and scan acquired after 30 mins- 1 hour. 1

Eligibility

Inclusion criteria

Inclusion criteria: Histologically confirmed metastatic ovarian adenocarcinoma at baseline who have now exhausted all conventional therapeutic options. Life expectancy greater than 12 weeks. Patients with metastatic ovarian adenocarcinoma who have progressed on 3 lines of chemotherapy. For [177Lu]Lu FAPI 46/FAP 2286 therapy, adequate end organ function as given by: Hemoglobin more than or equal to 10g/dl. Leucocytes more than or equal to 3000/mcL Platelets more than or equal to 75,000/mcL Total Bilirubin less than or equal to 3 x upper limit AST/ALT/ALP less than or equal to 3 x upper limit INR less than or equal to 1.5 x upper limit S. Creatinine less than or equal to 1.7 mg/dl

Exclusion criteria

Exclusion criteria: Eastern Cooperative Oncology Group [ performance status 2. Pregnant or lactating women. Refusal to give written informed consent or withdrawal of consent at any point of time. Recent anti cancer chemotherapy/surgery in less than four weeks or radiotherapy in less than 8 weeks. Active/acute serious illness/infection uncontrolled by oral medications. Concurrent primary malignancy other than ovarian adenocarcinoma.

Design outcomes

Primary

Measure	Time frame
To evaluate the diagnostic performance of [68 Ga]Ga FAPI 46/FAP 2286 PET/CT in comparison to [18 F]FDG PET/CT in metastatic ovarian adenocarcinoma patients. Timepoint: 0-12 months	—

Secondary

Measure	Time frame
To evaluate the feasibility and safety of the [177 Lu]Lu FAPI (FAPI-46/FAP-2286) therapy in patients with metastatic ovarian adenocarcinoma. To assess the efficacy of [177 Lu] Lu FAPI 46/FAP 2286 therapy using clinical parameters and PERCIST. To assess the quality of life and determine progression free survival after 177 [Lu]Lu FAPI 46/FAP 2286.Timepoint: 12-24 months	—

Countries

India

Contacts

Public ContactDr Parth Baberwal

All India Institute of Medical Sciences

sashamim2002@gmail.com9868350491

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026